Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNKS2 | Q9H2K2 | 8/20 | 0.65 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.63 |
| ▸ | HPGD | P15428 | 5/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.63 |
| ▸ | MAPT | P10636 | 2/20 | 0.63 |
| ▸ | GAA | P10253 | 1/20 | 0.61 |
| ▸ | HTT | P42858 | 1/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.60 |
| ▸ | TSHR | P16473 | 1/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | TNKS | O95271 | 1/20 | 0.50 |
| ▸ | PARP3 | Q9Y6F1 | 1/20 | 0.50 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7674194 | 0.88 | KDM4E (0.60) | TNKS2PBRM1KDM4EALDH1A1HPGD | |
| SCHEMBL13604402 | 0.84 | TNKS2 (0.64) | TNKS2PBRM1KDM4EALDH1A1HPGD | |
| SCHEMBL13599384 | 0.84 | KDM4E (0.63) | TNKS2PBRM1KDM4EALDH1A1HPGD | |
| SCHEMBL7667617 | 0.84 | TNKS2 (0.64) | TNKS2PBRM1KDM4EALDH1A1HPGD | |
| SCHEMBL7673041 | 0.84 | TNKS2 (0.64) | TNKS2PBRM1KDM4EALDH1A1HPGD | |
| SCHEMBL15033492 | 0.84 | TNKS2 (0.60) | TNKS2PBRM1KDM4EALDH1A1HPGD | |
| SCHEMBL11383047 | 0.79 | KDM4E (0.46) | TNKS2PBRM1KDM4EALDH1A1HPGD | |
| SCHEMBL24743516 | 0.79 | TNKS2 (1.00) | TNKS2PBRM1KDM4EALDH1A1HPGD | |
| SCHEMBL29801695 | 0.79 | TNKS2 (1.00) | TNKS2PBRM1KDM4EALDH1A1HPGD | |
| SCHEMBL29010889 | 0.79 | TNKS2 (1.00) | TNKS2PBRM1KDM4EALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9320815-B2 | Compounds and methods for enzyme-mediated tumor imaging and therapy | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2016-04-26 | — | — | US | disclosed |
| US-8394953-B2 | Compounds and methods for enzyme-mediated tumor imaging and therapy | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2013-03-12 | — | — | US | disclosed |
| US-20090324495-A1 | COMPOUNDS AND METHODS FOR ENZYME-MEDIATED TUMOR IMAGING AND THERAPY | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2009-12-31 | — | — | US | disclosed |
| US-6479499-B1 | INHIBITORS OF TUBULIN POLYMERIZATION | NATIONAL SCIENCE COUNCIL (TW) | 2002-11-12 | — | — | US | disclosed |
| US-4324682-A | PRESSURE RUPTURABLE; FOR MARKING AND IDENTIFICATION | AMERICAN CYANAMID COMPANY (US) | 1982-04-13 | — | — | US | disclosed |
| US-4219438-A | Composition for marking and identification purposes | AMERICAN CYANAMID COMPANY (US) | 1980-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090324495-A1 | COMPOUNDS AND METHODS FOR ENZYME-MEDIATED TUMOR IMAGING AND THERAPY | GAA, RNASE1, GUSB | TNKS2 808/4885PBRM1 1087/4885KDM4E 1946/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.